Bancroftian Filariasis in Zambia

1975 ◽  
Vol 69 (4) ◽  
pp. 521-522 ◽  
Author(s):  
P. R. Hira
Keyword(s):  
Bancroftian Filariasis

Unusual case of bancroftian filariasis co-existing with chronic myeloid leukemia

2014 ◽  
Vol 7 (1) ◽  
pp. 64
Author(s):  
PreetiRihal Chakrabarti ◽  
Mallika Kinger ◽  
Priyanka Kiyawat ◽  
Surabhi Sharma
Keyword(s):  
Chronic Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Unusual Case ◽  
Bancroftian Filariasis

Epidemiology of bancroftian filariasis in three suburban areas of Matara, Sri Lanka

2001 ◽  
Vol 95 (3) ◽  
pp. 263-273 ◽  
Author(s):  
M. V. Weerasooriya, T. R. Weerasooriya
Keyword(s):  
Sri Lanka ◽  
Bancroftian Filariasis ◽  
Suburban Areas

scholarly journals Acute eosinophilic glomerulonephritis with Bancroftian filariasis

1979 ◽  
Vol 55 (650) ◽  
pp. 905-907 ◽  
Author(s):  
A. Date ◽  
V. Gunasekaran ◽  
M. G. Kirubakaran ◽  
J. C. M. Shastry
Keyword(s):  
Bancroftian Filariasis

Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d'Ivoire

2021 ◽  
Author(s):  
Allassane F Ouattara ◽  
Catherine M Bjerum ◽  
Méité Aboulaye ◽  
Olivier Kouadio ◽  
Vanga K Marius ◽  
...  
Keyword(s):  
Lymphatic Filariasis ◽  
Primary Outcome ◽  
Central Africa ◽  
Wuchereria Bancrofti ◽  
Bancroftian Filariasis ◽  
Loa Loa ◽  
Open Label ◽  
Treatment Groups ◽  
Open Label Trial ◽  
To Receive

Abstract Background Ivermectin (IVM) plus albendazole (ALB), or IA, is widely used in mass drug administration (MDA) programs that aim to eliminate lymphatic filariasis (LF) in Africa. However, IVM can cause severe adverse events in persons with heavy Loa loa infections that are common in Central Africa. ALB is safe in loiasis, but more information is needed on its efficacy for LF. This study compared the efficacy and safety of three years of semiannual treatment with ALB to annual IA in persons with bancroftian filariasis. Methods Adults with Wuchereria bancrofti microfilaremia (Mf) were randomized to receive either three annual doses of IA (N=52), six semiannual doses of ALB 400mg (N=45), or six semiannual doses of ALB 800mg (N=47). The primary outcome amicrofilaremia at 36 months. Findings IA was more effective for completely clearing Mf than ALB 400mg or ALB 800mg (79%, CI 67-91; vs. 48%, CI 32-66 and 57%, CI 41-73, respectively). Mean % reductions in Mf counts at 36 months relative to baseline tended to be greater after IA (98%, CI 88-100) than after ALB 400mg (88%, CI 78-98) and ALB 800mg (89%, CI 79-99) (P=0.07 and P=0.06, respectively). Adult worm nest numbers (assessed by ultrasound) were reduced in all treatment groups. Treatments were well tolerated. Interpretation Repeated semiannual treatment with ALB is macrofilaricidal for W. bancrofti and leads to sustained reductions in Mf counts. This is a safe and effective regimen that could be used as MDA to eliminate LF in areas ivermectin cannot be used.

Bancroftian filariasis in two urban areas of Recife, Brazil: pre-control observations on infection and disease

1995 ◽  
Vol 89 (4) ◽  
pp. 373-377 ◽  
Author(s):  
M.F.M. Albuquerque ◽  
M.C. Marzochi ◽  
P.C. Sabroza ◽  
M.C. Braga ◽  
T. Padilha ◽  
...  
Keyword(s):  
Urban Areas ◽  
Bancroftian Filariasis

Bancroftian filariasis-differential reactivity of anti-sheath antibodies in microfilariae carriers

1994 ◽  
Vol 16 (6) ◽  
pp. 321-323 ◽  
Author(s):  
B. RAVINDRAN ◽  
A. K. SATAPATHY ◽  
P. K. SAHOO
Keyword(s):  
Bancroftian Filariasis ◽  
Differential Reactivity

Bancroftian filariasis in residents of Oman

Acta Tropica ◽  
2001 ◽  
Vol 79 (3) ◽  
pp. 241-244 ◽  
Author(s):  
E.M Scrimgeour ◽  
M.A Idris ◽  
B.M.S Al-Riyami ◽  
O.T El-Shafie ◽  
W.J Johnston ◽  
...  
Keyword(s):  
Bancroftian Filariasis
Sign in / Sign up

Export Citation Format

Share Document